Samsung Biologics (207940 KS): Raises 2023 Sales Guidance Second Time This Year; Buy the Dip
Samsung Bio raised 2023 sales forecast from 15–20% YoY growth to more than 20% YoY increase. Previously, in January, the company expected that this...
792 Views
Peptidream (4587 JP): Solid Revenue Growth Continued in 1H23; 2023 Guidance Remains Unchanged
In 1H23, revenue jumped 88% YoY, and both the operating and net losses have narrowed compared with 1H22. 2023 guidance calls for a 12% YoY revenue...
676 Views
Peptidream (4587 JP): 1Q23 Result- Radiopharma Drove Sales; Losses Narrowed; Guidance Reiterated
Peptidream recorded ¥5B revenue in 1Q23. While base business revenue jumped 133% YoY, acquired radiopharma contributed ¥4B revenue. Compared with...
385 Views
Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
Lotus has already created a compelling position in ASEAN, which has been further augmented by oral oncology drug launch in Europe. New ownership...
399 Views
Video: Cantargia - executive interview
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is...
667 Views